Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michelle Kisare
Observed names:
Kisare, Michelle,
M. Kisare
Institution:
ViiV Healthcare (United Kingdom)
Observed institution:
ViiV Healthcare (United Kingdom)
ORCID:
0009-0004-9413-5295
Observed ORCID:
0009-0004-9413-5295
OpenAlex ID:
A5049934351
Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review
2022
·
Josep M Llibre
, Pedro E Cahn
, et al.
·
Open Forum Infectious Diseases
·
42
PDF
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies
2024
·
Sharon Walmsley
, Don E. Smith
, et al.
·
AIDS Research and Therapy
·
13
PDF
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study
2024
·
Princy Kumar
, Amanda E. Clarke
, et al.
·
AIDS and Behavior
·
10
PDF
Very-Low-Level Viremia, Inflammatory Biomarkers, and Associated Baseline Variables: Three-Year Results of the Randomized TANGO Study
2023
·
Ruolan Wang
, Mark Underwood
, et al.
·
Open Forum Infectious Diseases
·
8
PDF
Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies
2024
·
C. Katlama
, F. Bisshop
, et al.
·
HIV Medicine
·
7
Efficacy and Safety Outcomes in Adults Initiating Dolutegravir/Lamivudine With High Viral Load in the GEMINI-1/-2 and STAT Trials
2025
·
Charlotte-Paige Rolle
, José R Arribas
, et al.
·
Open Forum Infectious Diseases
·
5
Pregnancy and Neonatal Outcomes After Prenatal Exposure to Dolutegravir: Findings from the Antiretroviral Pregnancy Registry
2026
·
Vani Vannappagari
, Jessica D. Albano
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
2
VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment
2026
·
Jade Ghosn
, Federico Pulido
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis
2024
·
Stefan Scholten
, Pedro Cahn
, et al.
·
Open Forum Infectious Diseases
·
1
Efficacité élevée du DTG/3TC chez les adultes naïfs de traitement avec une CV initiale élevée: analyses de sous-groupes à S48 des essais GEMINI-1/-2 et STAT
2023
·
C.-P. Rolle
, J. Arribas
, et al.
·
Médecine et Maladies Infectieuses Formation
Show more works
View as search
Works count:
13
Citation count:
89
H-index:
5
I10-index:
3
Year
Topic
Type